Skip to main content
PURE logo

PURE Bioscience, Inc. (PURE) Stock Price & Analysis

PURE Bioscience, Inc. (PURE) — price $0.05 (-13.79%), as of the Nov 19, 2026 trading session; market cap $7.01M.

Educational signal · not a buy or sell recommendation · How to read this

$0.05 −$0.008 (-13.79%) Market Cap $7.01M

PURE Bioscience, Inc. · PURE

PURE Bioscience, Inc. develops and commercializes antimicrobial products, focusing on its proprietary silver dihydrogen citrate (SDC) technology. The company's products cater to health and environmental challenges related to pathogen control across various industries.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • TANH · Tantech Holdings Ltd · 34 /100
  • AXIL · AXIL Brands, Inc. · 84 /100
  • UG · United-Guardian, Inc. · 83 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.05
Change on the day-13.79%
Market capitalisation$7.01M—
Shares traded on the day56.2K

Price & events

Other perspectives

Council score for PURE Bioscience (PURE): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is PURE Bioscience (PURE), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. PURE Bioscience, Inc. (PURE) is the company analyzed here. It employs 10 people. In Q4 FY2026 it reported revenue of $660,000 and net income of -$610,000. The market values it at $7.01M.

2 · Latest results

What do the latest results show for PURE Bioscience (PURE)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of $660,000.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026$660,000-$610,000-$0.0047 (diluted)
Q3 FY2026$506,000-$624,000-$0.01 (diluted)
Q2 FY2026$444,000-$785,000-$0.01 (diluted)
Q1 FY2026$708,000-$464,000-$0.0041 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for PURE Bioscience (PURE)?

Short answer · as of

The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 41.3% · current ratio 0.27 · earnings yield -32.8% · free-cash-flow yield -20.6%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PURE in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PURE in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About PURE

These answers are editorial: 2 of these 8 answers are drawn from the PURE research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 6 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is PURE a good stock to buy?

Stock Expert AI does not rate PURE buy, sell or hold. PURE Bioscience, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PURE stock price today?

The last price recorded for PURE Bioscience, Inc. (PURE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about PURE stock?

Analyst coverage of PURE Bioscience, Inc. is limited due to its micro-cap status and OTC listing. However, key valuation metrics to consider include its market capitalization, revenue growth, and gross margin. The company's high gross margin suggests potential for profitability as revenue scales.

What are the main risks for PURE?

The main risks for PURE Bioscience, Inc. include its negative profitability, limited market share, and reliance on a single technology (SDC). Regulatory changes could impact the use of SDC. As an OTC-listed company, PURE is subject to lower trading volume and liquidity, which can increase price volatility.

What are the key factors to evaluate for PURE?

Evaluate PURE on fundamentals, analyst consensus, and risk factors. Adapting its products to meet local regulations and consumer preferences is crucial for success. Not financial advice.

How frequently does PURE data refresh on this page?

PURE's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PURE's recent stock price performance?

PURE Bioscience, Inc. (PURE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SDC technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PURE overvalued or undervalued right now?

PURE Bioscience, Inc. (PURE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 11 figures on this page — 8 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.